Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

Bortezomib (BZM) is the first proteasome inhibitor approved for relapsed Mantle Cell Lymphoma (MCL) with durable responses seen in 30%–50% of patients. Given that a large proportion of patients will not respond, BZM resistance is a significant barrier to use this agent in MCL. We hypothesized that a...

Descripción completa

Detalles Bibliográficos
Autores principales: Leshchenko, Violetta V., Kuo, Pei-Yu, Jiang, Zewei, Weniger, Marc A., Overbey, Jessica, Dunleavy, Kieron, Wilson, Wyndham H., Wiestner, Adrian, Parekh, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694993/
https://www.ncbi.nlm.nih.gov/pubmed/25714012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694993/
https://www.ncbi.nlm.nih.gov/pubmed/25714012

Ejemplares similares